Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing the country’s leading biopharmaceutical research companies, supports the FDA's Draft Guidance on using AI for regulatory decision-making. They praise the risk-based "Credibility Framework" but request further clarity on specific definitions, risk assessment criteria, and the handling of third-party and foundation models.